Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Relative Bioavailability of Obefazimod Minitablet in Healthy Participants
NCT07453784Phase 1Recruiting
- Sponsor
- Abivax
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of obefazimod in ulcerative colitis (UC) (2 arms), sponsored by Abivax. Primary endpoints: Maximum Plasma Concentration, Area under the plasma concentration versus time curve from time zero up to the last measurable concentration and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07453784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07453784.